PMID- 36852040
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230301
IS  - 2405-8440 (Print)
IS  - 2405-8440 (Electronic)
IS  - 2405-8440 (Linking)
VI  - 9
IP  - 2
DP  - 2023 Feb
TI  - Synthesis and characterization of bovine serum albumin-coated copper sulfide 
      nanoparticles as curcumin nanocarriers.
PG  - e13740
LID - 10.1016/j.heliyon.2023.e13740 [doi]
LID - e13740
AB  - Cancer is among the most common causes of death in the world that affects a large 
      number of people every year. Curcumin is one of the natural anticancer 
      therapeutics with little or no negative effects. However, due to its hydrophobic 
      nature, poor bioavailability, limited gastrointestinal uptake, and fast 
      metabolism, its therapeutic applications are constrained. Therefore, the Bovine 
      Serum Albumin-Coated Copper Sulfide anoparticles (CuS@BSA) for curcumin (CUR) 
      drug delivery were synthesized and characterized, and then curcumin release from 
      the nanosystem. Hemotoxicity, and cytotoxicity was investigated. This study 
      involved the one-step synthesis of CuS@BSA nanoparticles first, followed by the 
      addition of CUR. Then the synthesized nanoparticles were characterized employing 
      Scanning Transient Electron Microscopy (STEM), Ultraviolet-visible spectroscopy 
      (UV-vis) and Fourier-transform infrared spectroscopy (FT-IR) techniques. The Size 
      and surface charge (zeta potential) of synthesized nanoparticles were determined 
      by Dynamic Light Scattering (DLS) to be 120 nm and -13 eV, respectively. The 
      results showed that the CUR loading was around 15% and also the release pattern 
      of CUR was dependent on pH and increased in an acidic environment. The results of 
      the hemolysis assay showed that the synthesized nanoparticles are not hemotoxic. 
      The investigation of the cytotoxic effects of synthesized nanoparticles on cancer 
      cells demonstrated that CuS@BSA nanoparticles did not exhibit any toxicity and 
      therefore are an appropriate candidate for drug delivery.
CI  - (c) 2023 Published by Elsevier Ltd.
FAU - Mohammadi, Ali
AU  - Mohammadi A
AD  - Student Research Center, Zanjan University of Medical Sciences, Zanjan, Iran.
AD  - Zanjan Pharmaceutical Nanotechnology Research Center, Zanjan University of 
      Medical Sciences, Zanjan, Iran.
FAU - Danafar, Hossein
AU  - Danafar H
AD  - Student Research Center, Zanjan University of Medical Sciences, Zanjan, Iran.
AD  - Zanjan Pharmaceutical Nanotechnology Research Center, Zanjan University of 
      Medical Sciences, Zanjan, Iran.
LA  - eng
PT  - Journal Article
DEP - 20230214
PL  - England
TA  - Heliyon
JT  - Heliyon
JID - 101672560
PMC - PMC9957751
OTO - NOTNLM
OT  - Albumin
OT  - Copper
OT  - Curcumin
OT  - Cytotoxicity
OT  - Drug delivery
OT  - Nanoparticles
COIS- The authors declare no conflict of interest.
EDAT- 2023/03/01 06:00
MHDA- 2023/03/01 06:01
PMCR- 2023/02/14
CRDT- 2023/02/28 02:14
PHST- 2022/11/20 00:00 [received]
PHST- 2023/02/04 00:00 [revised]
PHST- 2023/02/09 00:00 [accepted]
PHST- 2023/02/28 02:14 [entrez]
PHST- 2023/03/01 06:00 [pubmed]
PHST- 2023/03/01 06:01 [medline]
PHST- 2023/02/14 00:00 [pmc-release]
AID - S2405-8440(23)00947-7 [pii]
AID - e13740 [pii]
AID - 10.1016/j.heliyon.2023.e13740 [doi]
PST - epublish
SO  - Heliyon. 2023 Feb 14;9(2):e13740. doi: 10.1016/j.heliyon.2023.e13740. eCollection 
      2023 Feb.